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Screening of transdermal formulations during the preliminary phase frequently re-
quires animal skin samples. But, animal skin differs significantly from human skin due
to the differences in thickness, nature of stratum corneum, density of hair follicles and
sweat glands (1). This makes extrapolation of in vitro data to in vivo performance less re-
liable. In addition, various factors, like race, sex, age and anatomical site of skin, influ-
ence the reproducibility as well as reliability of data obtained from in vitro experiments.
Furthermore, availability of both human cadaver and animal skin is becoming highly re-
stricted.
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The present investigation is aimed at preparing chitosan
films capable of simulating the flux of modal drugs, 5-fluo-
rouracil (5-FU) and indomethacin (INDO), across rat, rab-
bit and human cadaver epidermal sheets. Application of
statistical design revealed that the concentration of chi-
tosan, crosslinking time and concentration of crosslinking
agent significantly influenced the in vitro flux of 5-FU and
INDO across chitosan films. Multiple linear regression
revealed a linear influence of all these active variables on
5-FU and INDO flux. It was deduced from atomic ab-
sorption spectroscopic analyses, DSC and IR spectroscopic
data that 5% (m/V) sodium tripolyphosphate (NaTPP)
produced optimum crosslinking of chitosan films. The in
vitro permeation of both 5-FU and INDO across optimized
film formulations was found to be comparable to that
obtained across rat, rabbit and human epidermal sheets.
These results indicate that optimized chitosan films have
a potential to be developed as a substitute for animal and
human cadaver epidermal sheets for preliminary in vitro
permeation studies.
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These problems can be to a large extent overcome by using artificial films in place of
animal skin. Artificial membranes possess a distinct advantage over biological membra-
nes, such as controlled composition, ease of preparation and reproducibility of results
(2). Therefore, such films can serve as an alternative to animal skin during in vitro testing
of transdermal formulations, thereby reducing or even obliterating the use of animal
skin in preliminary studies.
Chitosan is a linear polysaccharide, which is reported to form complexes with so-
dium carboxymethylcellulose, citrates, pectin, acacia, agar, sodium caprylate, stearic acid,
glutaraldehyde, sodium tripolyphosphate, lactic acid, malic acid and alginic acid (3–7).
These chitosan complexes are insoluble in alkaline buffer. This property of complexed
chitosan has been utilized in preparing beads (8, 9), microspheres (10, 11) and artificial
films (12–14).
Earlier investigations using chitosan membranes have proved useful in simulating
drug permeation across rat epidermis (6). Hence, it can be hypothesized that suitably
cross-linked chitosan films could be used for stimulating drug permeation across epi-
dermal sheets obtained from other species as well.
The present investigation employed statistical optimization designs for identifying
critical formulation and process variables capable of influencing permeation of 5-fluo-
rouracil (5-FU) and indomethacin (INDO), model polar and non polar drugs, respecti-
vely, across formulated chitosan films. This was done with an aim to optimize the active
variables for preparing chitosan films capable of simulating the flux of both drugs across
rat, rabbit and human cadaver epidermal sheets.
EXPERIMENTAL
Chitosan, 95% deacetylated (Central Institute of Fisheries Technology, India), 5-fluo-
rouracil (Dabur Research Foundation, India), indomethacin (Crystal Pharmaceuticals,
India), sodium tripolyphosphate and glacial acetic acid (Loba Chemie, India) were used
as received. All other reagents were of analytical grade.
Preparation of epidermal sheets
Animal (rat/rabbit) skin was obtained after sacrificing the animal by administration
of excess chloroform for inhalation. Human cadaver skin (male) was obtained post-mor-
tem within 6 h of death from the local medical college after obtaining the consent of the
relatives of the deceased. These protocols were approved by the respective institutional
ethical committees. Dorsal skin portion of albino Wistar rats or rabbits was shaved with
an electrical hair clipper and excised after sacrificing. Human cadaver skin was excised
from the abdominal/chest portion. Epidermal sheet was separated by soaking the ex-
cised whole skin in phosphate buffer saline (PBS, pH 7.4) containing trypsin (0.1%, m/V)
for 120 s at 60 °C.
Freshly prepared epidermal sheets were washed with PBS and conditioned under
stirring in a receptor solution for 4 h before commencing in vitro permeation experi-
ments.
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Formulation design and preparation of cross-linked chitosan films
For screening the effect of the process and formulation variables (15) on permeation
parameters of 5-fluorouracil and indomethacin, the Plackett-Burman screening design
(PBD) was used. PBD is a useful experimental design employed to screen various for-
mulation and process variables for their influence on particular responses by conducting
a minimum number of experiments. Various chitosan films were prepared by using low
and high levels (designated –1 and +1, respectively) of each variable (X1–X8). The film
formulations (P1–P8) prepared according to PBD are summarized in Table I. The active
variables (that significantly influence the response) may show their effect/interaction in
any part of the experimental domain ranging between their low and high levels. In order
to investigate the influence of these active variables (concentration of chitosan, concen-
tration of cross-linking agent and cross-linking time) on the permeation of both drugs in
the entire experimental domain, experiments were performed using a central composite
design (CCD). Additional films (Table II) were prepared using the 23 factorial design
(1F–8F), six star design or axial points (1S–6S) and centre point (1C–4C) in order to com-
plete the CCD covering the entire experimental domain. Permeation of both drugs across
the films was compared with that obtained across rat/rabbit/human epidermal sheets.
Correlation between active variables obtained from CCD and in vitro flux of both drugs
was done employing Statistica software-5.0 (Sta Soft Inc., USA).
All the chitosan films were prepared by the following method. Solution of chitosan
(2.5–4%, m/V) was prepared in acetic acid (3–20%, m/V) and homogenized (2000 rpm). It
was filtered through muslin cloth to remove debris and a portion (15 mL) was degassed
under vaccum. This solution was cast into a glass ring (cross sectional area 3.14 cm2) fit-
ted on a polycarbonate Petri dish and subjected to drying. The dried membranes (45 °C
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Table I. Screening design for identifying active formulation and process variables influencing the flux

















P1 +1 (4) +1 (10) +1 (45) –1 (24) –1 (3) +1 –1 50.4 ± 12.4 1.045 ± 0.046
P2 –1 (2.5) +1 (10) +1 (45) +1 (48) +1 (20) –1 –1 142.7 ± 5.6 2.947 ± 0.045
P3 –1 (2.5) –1 (5) +1 (45) +1 (48) –1 (3) +1 +1 44.8 ± 3.6 2.022 ± 0.010
P4 +1 (4) –1 (5) –1 (15) +1 (48) +1 (20) +1 –1 64.5 ± 0.2 1.853 ± 0.003
P5 –1 (2.5) +1 (10) –1 (15) –1 (24) +1 (20) +1 +1 214.0 ± 0.2 3.280 ± 0.008
P6 +1 (4) –1 (5) +1 (45) –1 (24) +1 (20) –1 +1 56.4 ± 2.7 0.699 ± 0.014
P7 +1 (4) +1 (10) –1 (15) +1 (48) –1 (3) –1 +1 88.0 ± 0.5 1.851 ± 0.002
P8 –1 (2.5) –1 (5) –1 (15) –1 (24) –1 (3) –1 –1 141.5 ± 5.1 2.416 ± 0.097
X1 – concentration of chitosan, X2 – concentration of NaTPP, X3 – crosslinking time, X4 – drying time at 45 °C,
X5 – concentration of acetic acid, X6, X7 – dummy variables, +1 and –1 are transformed values of real experi-
mental values shown in parentheses
a Values represent mean ± SD of 5 experiments.
for 24–48 h) were stored in polyethylene bags until used. Cross-linking of chitosan films
was done by dipping in a sodium tripolyphosphate (NaTPP) solution (10 mL of 1–20%,
m/V, for 15–45 min). These films were washed with water to remove excess NaTPP.
Freshly crosslinked membranes that were insoluble in the receptor solution (phosphate
buffer pH 7.4) for more than 48 h were used for in vitro permeation experiments.
Physicochemical characterization of films
Atomic absorption spectroscopy for Na+ in chitosan films. – Chitosan films were prepa-
red by dissolving chitosan (4%, m/V) in 15 mL of 3% (V/V) acetic acid. They were dried
at 45 °C for 24 h and cross-linked by dipping in 10 mL NaTPP solution (1, 5, 10 or 20%,
m/V) for 45 min. Each cross-linked film was dissolved in 2 mL of aqua regia and evapo-
rated to dryness on a water bath. The residue was cooled, dissolved in 10 mL of HCl
(50%, V/V) and filtered through a G3 filter. The filtrate obtained was subjected to flame
atomic absorption spectroscopy for estimation of Na+ (GBC, 932AAS, Australia).
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Table II. Central composite design using active formulation and process variables influencing the flux













1F –1 (2.5) –1 (5) –1 (15) 2.416 ± 0.097 141.5 ± 5.1
2F +1 (4) –1 (5) –1 (15) 1.853 ± 0.002 64.5 ± 0.2
3F –1 (2.5) +1 (10) –1 (15) 3.280 ± 0.008 214.0 ± 0.2
4F +1 (4) +1 (10) –1 (15) 1.851 ± 0.002 88.0 ± 0.5
5F –1 (2.5) –1 (5) +1 (45) 2.023 ± 0.010 44.8 ± 3.6
6F +1 (4) –1 (5) +1 (45) 0.699 ± 0.014 56.4 ± 2.7
7F –1 (2.5) +1 (10) +1 (45) 2.947 ± 0.045 142.7 ± 5.5
8F +1 (4) +1 (10) +1 (45) 1.045 ± 0.046 50.4 ± 1.2
1S –1.682 (2) 0 (7.5) 0 (30) 2.894 ± 0.050 168.3 ± 2.3
2S +1.682 (4.5) 0 (7.5) 0 (30) 1.341 ± 0.056 55.7 ± 0.7
3S 0 (3.25) –1.682 (3.3) 0 (30) 1.589 ± 0.023 63.5 ± 0.6
4S 0 (3.25) +1.682 (11.7) 0 (30) 2.921 ± 0.090 160.6 ± 4.9
5S 0 (3.25) 0 (7.5) –1.682 (5) 3.942 ± 0.069 134.7 ± 7.3
6S 0 (3.25) 0 (7.5) +1.682 (55.2) 1.658 ± 0.044 52.5 ± 1.1
1C 0 (3.25) 0 (7.5) 0 (30) 2.320 ± 0.006 98.4 ± 1.4
2C 0 (3.25) 0 (7.5) 0 (30) 2.310 ± 0.012 98.5 ± 1.3
3C 0 (3.25) 0 (7.5) 0 (30) 2.314 ± 0.009 98.6 ± 1.2
4C 0 (3.25) 0 (7.5) 0 (30) 2.310 ± 0.012 98.3 ± 1.4
For X1 – X3 see Table I. F – factorial design, S – star design, C – centre points
a Values represent mean ± SD of 5 experiments.
Infrared absorption spectroscopy. – The cross-linked chitosan films as prepared for ato-
mic absorption spectroscopy were dried to constant mass at 45 °C. Then they were tri-
turated with an equal quantity of KBr and compressed to obtain discs for IR analysis.
The spectra of these discs were recorded on a Perkin Elmer RXI, IR spectrophotometer
(USA) in the spectral region of 500 to 4000 cm–1.
Differential scanning calorimetry. – Cross linked films (as prepared for IR spectrosco-
py) were also subjected to DSC studies. Samples of chitosan powder and cross-linked
films were stored in a desiccator at 50% RH for 48 h. Then they were subjected to DSC
analysis (Mettler Toledo Star System, 821E, Switzerland) employing a heating rate of 10
°C min–1.
In vitro permeation studies. – A vertical Franz diffusion cell apparatus was designed
and fabricated in our laboratory. It consisted of 8 glass diffusion cells (20 mL each). Stir-
ring of the receptor fluid in each cell was done by magnetic stirrers (300 rpm) at a tem-
perature of 37  0.5 °C by a water heating system. Chitosan membranes or epidermal
sheets were clamped between donor and receptor compartments. The receptor compart-
ment contained phosphate buffer (pH 7.4), sodium azide (0.5%, m/V) and PEG 400 (5.0%,
V/V). Each drug was suspended in propylene glycol (4 mL) and loaded in the donor
compartment. Aliquots (1 mL) withdrawn at various intervals were immediately ana-
lyzed for 5-FU or INDO by HPLC (Waters 515 pump, USA) using Spherisorb C18 column
(4.6  250 mm) and UV detector (2487 Dual wavelength). Sodium acetate (0.1%, m/V)
and methanol/citrate buffer 10 mmol L–1 (75:25), at flow rates of 0.6 mL min–1 and 1.0
mL min–1, were used as mobile phases for 5-FU and INDO, respectively. The respective
detection wavelengths were 265 and 240 nm, as reported by Sasaki et al. (16).
Statistical analysis
All possible pairs consisting of the means of Tm (peak transition temperature), H
(enthalpy of transition) or in vitro flux were subjected to the t-test to test the difference at
5% level of significance.
RESULTS AND DISCUSSION
Preliminary studies were carried out to evaluate the influence of the formulation
and process variables on the permeation of 5-FU and INDO across NaTPP cross-linked
chitosan films. Data on permeation through chitosan films formulated according to the
Plackett-Burman design revealed that the concentration of chitosan, cross-linking time
and concentration of cross linking agent influenced the flux (slope of the linear portion
of the cumulative amount permeated vs. time) of both 5-FU (model polar drug) and INDO
(model non polar drug). These data are summarized in Table I. The effect of various for-
mulation and process variables (X1…X7) on 5-FU flux (Y1) across chitosan films was
found to be represented by the equation: Y1 = 2.0143 – 0.6521X1 + 0.2665X2 – 0.3359X3 +
0.1542X4 + 0.1806X5 + 0.036X6 – 0.051X7 and that for INDO flux (Y2) by the equation: Y2
= 100.2 – 35.46X1 + 23.48X2 – 26.71X3 – 15.29X4 + 19.113X5 – 6.86X6 + 0.513X7. Three fac-
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tors that were found active from the PBD were further studied by preparing additional
formulations (Table II) using the central composite design. Multiple linear regression of
the data obtained from CCD revealed that the influence of all the active variables on the
flux of both drugs was independent of each other (15). The data show that the flux of
5-FU and INDO decreased linearly with an increase in chitosan concentration and cross-
linking time (low level to high level). However, the flux was found to increase with an
increase in the concentration of the cross-linking agent (Tables I and II).
The unexpected increase of 5-FU and INDO flux with increasing the concentration
of the cross-linking agent seems to be due to the influence of the negative charge devel-
oped on chitosan films as a consequence of cross-linking with sodium tripolyphosphate.
Chitosan in solid state contains amino groups. When dissolved in acetic acid, the –NH2
groups get converted to CH3COO– NH3+–. Therefore, chitosan itself, when dissolved in
acetic acid, develops a net positive charge (5). It is logical to expect that upon cross-link-
ing, CH3COO¯ ions present in chitosan films will be replaced with NaTPP (cross-linking
agent).
Atomic absorption spectroscopy data show that an increase in NaTPP concentration
during cross linking increased the Na+ content (the counter ion) in cross-linked chitosan
films (Table III). It seems that at a low NaTPP concentration, the crosslinking was of the
–NH3+ ¯OPO2 – PO2¯ _ O2PO¯ + NH3– type. Thus, with an increase in NaTPP concentra-
tion, the net charge on cross-linked films is expected to shift from positive to negative
due to the attachment of –PO3¯ moieties. Availability of extra CH3COO– NH3+– groups in
the chitosan molecule seems to result in linkage of two terminal –PO3¯ moieties of the
NaTPP molecule with two CH3COO–NH3+– moieties of two chitosan monomers, one on
each side. As the concentration of NaTPP increased, only one terminal –PO3¯ moiety got
attached to one CH3COO– NH3+– moiety of each chitosan monomer. This, perhaps, al-
tered the previous linkage to –NH3+ ¯OPO2 – PO2¯_ O2PO¯ +Na. This explanation was
supported by the findings of IR spectroscopy. The flux of 5-FU and INDO across films
crosslinked with 1% (m/V), NaTPP was found to be the highest. This could be attributed
to improper crosslinking at a low NaTPP concentration. Increase in NaTPP concentra-
tion (5%, m/V) is expected to decrease the positive charge on chitosan film. However, it
can be envisaged to be still high enough to interact with and restrict the movement of
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First endotherm Second endotherm
Tm (°C) H (J g–1) Tm (°C) H (J g–1)
1 6.3 ± 0.1 2.912 ± 0.006 98.4 ± 0.6 79.8 ± 1.2 80.8 ± 1.2 228.6 ± 8.7 39.5 ± 3.1
5 44.6 ± 5.6 0.683 ± 0.003 50.4 ± 4.4 55.3 ± 1.2 1.9 ± 2.3 220.3 ± 2.3 168.9 ± 2.0
10 46.0 ± 1.3 1.107 ± 0.010 63.4 ± 3.2 63.6 ± 1.1 94.3 ± 3.2 244.8 ± 8.9 55.1 ± 5.6
20 60.3 ± 2.2 2.651 ± 0.008 88.0 ± 0.5 59.7 ± 1.5 86.0 ± 3.3 243.8 ± 9.3 52.1 ± 9.3
a Values represent mean ± SD of 5 experiments.
negatively charged 5-FU and INDO species. Therefore, this interaction seems to be respon-
sible for decreasing 5-FU and INDO flux across chitosan films crosslinked with 5% (m/V)
NaTPP to a minimum value. Hence, crosslinking with 5% (m/V), NaTPP appears to indi-
cate the most useful crosslinking of chitosan with NaTPP. However, further increase in
NaTPP concentration (10 and 20%, m/V) resulted in an enhanced passage of 5-FU and
INDO across the films. This might be due to the increased negative charge on the film
(due to excessive presence of –PO3¯ moieties) that repelled the negatively charged 5-FU-
/INDO molecules across the film. It is important to note that Remunan-Lopez and Bod-
meier (14) observed the diffusion of chlorpheniramine maleate (a basic drug) that is posi-
tively charged in chitosan films to decrease with an increase in NaTPP concentration.
Therefore, enhanced permeation of both 5-FU and INDO across chitosan films cross-
-linked with an increasing concentration of NaTPP can be ascribed to their acidic nature
due to which both drugs will be negatively charged in the films and hence, repelled into
the receptor compartment. Therefore, these findings are in agreement with those of Re-
munan-Lopez and Bodmeier (14). Hence, the overwhelming role of the concentration of
the crosslinking agent in controlling the permeation of 5-FU and INDO across chitosan
films was evident.
The IR spectra showed peaks at 1060–1300 cm–1, suggesting the presence of phos-
phonate linkage between –NH3+ of chitosan and –PO3¯ moieties of NaTPP during the
crosslinking process. Only one peak at 1120 cm–1 was observed in the film when cross-
linked with 1% (m/V) NaTPP, indicating no appreciable linkage. However, the films cross-
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Fig. 1. IR spectra of: A) chitosan powder, and chitosan
(4%, m/V) films cross-linked with NaTPP (%, m/V): B)
1, C) 5, D) 10 and E) 20.
linked by 5%, m/V, NaTPP showed two peaks, at 1140 cm–1 and at 1280 cm–1 (Fig. 1), in-
dicative of symmetric and antisymmetric stretching of phosphonate linkage, respectively.
The latter peak (antisymmetric) is known to occur due to restricted rotation (17). There-
fore, the two terminal –PO3¯ moieties of the NaTPP molecule seem to be linked with two
CH3COO– NH3+– moieties of two chitosan monomers, one on each side. This crosslink-
ing perhaps restricted the permeation of drug molecules and resulted in the lowest flux
of both drugs across films crosslinked with 5% (m/V) NaTPP. These two peaks were also
observed in films crosslinked with 10% (m/V) NaTPP. However, the intensity of the anti-
symmetric peak was significantly reduced. This antisymmetric peak was found to merge
into a single broad band at 1060 cm–1, indicating the absence of restricted rotation in
films crosslinked with 20% (m/V) NaTPP. In consonance, greater permeation of both drugs
was observed across films crosslinked with either 10 or 20% (m/V) NaTPP.
DSC thermograms of all the crosslinked films exhibited two endotherms (Fig. 2).
The first endotherm obtained below 100 °C could be attributed to water loss since all the
films were saturated in 50% RH prior to thermal analysis. A statistically significant dif-
ference at 5% level of confidence was observed for the second endothermic Tm values of
films cross-linked with 1, 5 or 10 (m/V) NaTPP. Tm values followed the order: 10  20 > 1
> 5% (m/V) NaTPP. H for this endotherm was found to be 39.47, 168.93, 55.06 and 52.09
J g–1 for films cross-linked with 1, 5, 10, 20% m/V NaTPP, respectively. Significantly dif-
ferent were the H values for films cross-linked with 1 or 5 (m/V) NaTPP. No significant
difference was detected for either Tm or H values of films cross-linked with 10 and 20%
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Fig. 2. DSC thermograms of: A) chitosan powder, and
chitosan (4%, m/V) films cross-linked with NaTPP (%,
m/V): B) 1, C) 5, D) 10 and E) 20.
(m/V) NaTPP. It is noteworthly that different concentrations of NaTPP significantly in-
fluenced the in vitro flux of both 5-FU and INDO across films (Table III). In vitro flux values
followed the order: 1 > 20 > 10 > 5% (m/V) NaTPP. Hence, the cross-linking of chitosan
by 5% (m/V) NaTPP (reflected in the highest H value of the second endotherm) appears
to result in the lowest permeation of both drugs.
The three equations generated using the statistical software for both drugs (Table
IV) were solved to calculate the optimum values of X1 (concentration of chitosan), X2
(concentration of crosslinking agent) and X3 (crosslinking time) for preparing chitosan
films that will exhibit a flux comparable to that across epidermal sheets. The lower and
higher solved values of all the active variables (X1, X2, X3) summarized in Table IV were
employed to prepare films in order to simulate the in vitro flux of 5-FU or INDO across
rat, rabbit and human cadaver epidermal sheets. Table V shows that the permeation of
both 5-FU and INDO across cross-linked chitosan films formulated using various opti-
mized values of active variables did not differ significantly as compared to that across
rat/rabbit/human epidermal sheets.
It is important to note that the optimized values for preparing chitosan films capa-
ble of simulating the flux of either drug are different for epidermal sheets of different
animals. This indicates that a single chitosan film with a particular optimized composi-
tion cannot be used for simulating drug permeation across all types of epidermis. This is
because of the different inherent permeabilities of the epidermis of different animals due
to variation in their biochemical constituents, anatomical ultrastructure, etc. Neverthe-
less, a high correlation evident from Fig. 3 and Fig. 4 suggests that NaTPP cross-linked
chitosan films prepared by using their optimized composition can be used to simulate
the in vitro permeation of 5-FU and INDO across rat, rabbit and human cadaver epider-
mal sheets.
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Table IV. Equations for relating the influence of the concentration of chitosan (X1), cross-linking
agent (X2) and cross-linking time (X3) on the flux of 5-FU (Y1) and INDO (Y2) across cross-linked
chitosan films
Treatment Equation
X1 vs. X2 Y1 = 2.206 + 0.573X1 + 0.320X2 Y2 = 101.744 + 34.638X1 + 25.715X2
X2 vs. X3 Y1 = 2.206 + 0.320X2 + 0.478X3 Y2 = 101.744 + 25.715X2 + 25.769X3
X3 vs. X1 Y1 = 2.206 + 0.573X1 + 0.478X3 Y2 = 101.744 + 34.638X1 + 25.769X3
















Rat 3.00–3.25 6.3–7.5 25–30 3.12–3.18 7.0–7.2 26.6–28.0
Rabbit 3.44 8.7 35 4.40–4.60 12.7–13.5 62.0–66.0
Human 2.20–2.30 1.5–1.8 6–8 2.50–2.55 4.1–4.3 9.5–11.3
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Table V. Optimized composition of cross-linked chitosan films capable of mimicking the 5-FU and
INDO flux across rat, rabbit and human epidermis






5-Fluorouracil (mg h–1 cm–2)
RAT 2.05 ± 0.15 2.13 ± 0.66 NS
Rabbit 2.47 ± 0.03 2.70 ± 0.94 NS
Human 0.72 ± 0.03 0.76 ± 0.23 NS
Indomethacin (g h–1 cm–2)
Rat 92.6 ± 2.5 97.23 ± 0.56 NS
Rabbit 217.6 ± 7.5 220.60 ± 0.52 NS
Human 34.2 ± 3.2 31.66 ± 0.13 NS
Comparison between epidermal sheets and optimized films: NS – no statistically significant difference.
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Fig. 3. Correlation between in vitro permeation
of 5-FU across optimized chitosan films and
rat epidermal sheet (Y = 0.956 X + 4.682, R2 =
0.96), rabbit epidermal sheet (Y = 1.0225 X –
0.4292, R2 = 1.00) and human cadaver epider-
mal sheet (Y = 1.048 X + 0.097, R2 = 0.99). Each
print values mean  SD, n = 5.
CONCLUSIONS
NaTPP may critically influence the permeation of both hydrophilic and lipophilic
drugs across chitosan films. The findings of in vitro permeation studies were explained
on the basis of the contribution of charge to the film by increasing concentration of NaTPP
and the evidence obtained from atomic absorption spectroscopy, IR spectroscopy and DSC
analysis of cross-linked films. Further, the results suggest that the formulation and pro-
cess variables can be modified to prepare NaTPP cross-linked chitosan films that simu-
late the in vitro permeation of polar and non polar drug species across animal and human
epidermal sheets. This knowledge has a great potential for exploitation in transdermal
dosage form research for making films as an alternative to animal and human skin. This
is expected to reduce the widespread use of natural skin during preliminary in vitro in-
vestigations on transdermals.
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S A @ E T A K
Optimizacija kitozanskih filmova kao zamjena za `ivotinjsku i humanu
epidermu za in vitro permeaciju polarnih i nepolarnih lijekova
VIKAS RANA, KUMAR BABITA, DINESH GOYAL, RAKESH GOREA i ASHOK TIWARY
U radu je opisana priprava kitosanskih filmova pogodnih za simulaciju prijelaza
modelnih lijekova, 5-fluorouracila (5-FU) i indometacina (INDO), kroz epidermalne slo-
jeve {takora, zeca i ~ovjeka. Koncentracija kitosana, vrijeme umre`avanja i koncentracija
reagensa za umre`avanje zna~ajno su utjecale na in vitro prolaz 5-FU i INDO kroz kito-
sanske filmove. Multiplom linearnom regresijom pokazano je da sve navedene varijable
imaju linearni utjecaj na prolaz 5-FU i INDO. Uz pomo} atomske apsorpcijske spektral-
ne analize, DSC i IR spektroskopskih podataka zaklju~eno je da je 5%-tna (m/V) otopina
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natrijevog tripolifosfata (NaTPP) optimalna za umre`avanje kitosanskih filmova. Prona-
|eno je da je in vitro permeacija 5-FU i INDO kroz optimiziranu formulaciju kitozanskog
filma usporediva s permeacijom kroz epidermalne slojeve {takora, zeca i ~ovjeka. Re-
zultati upu}uju na to da se optimizirani kitozanski filmovi mogu upotrijebiti kao nado-
mjestak animalne i humane epiderme u preliminarnim in vitro permeacijskim istra`iva-
njima.
Klju~ne rije~i: kitosanski filmovi, natrijev tripolifosfat, epiderma {takora, epiderma zeca, humana
epiderma
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